The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Abstract
Mouse double minute 2 (MDM2) is an oncogenic E3 ligase that effectively degrades the tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt MDM2-p53 binding have been discovered and developed. Given that MDM2 and p53 form an auto-regulatory loop, in which p53 undergoes targeted degradation as a substrate of MDM2, and p53 targets MDM2 for transcriptional upregulation, these MDM2 inhibitors have limited efficacy. After rapid in vivo clearance of the MDM2 inhibitors, p53 is degraded by accumulated MDM2. Fortunately, proteolysis targeting chimeras (PROTACs), a novel therapeutic strategy, overcome the limitations of MDM2 inhibitors. Several MDM2 inhibitors developed in the past two decades have been used in PROTAC technology in two applications: 1) binding and targeting endogenous MDM2 for PROTAC-based degradation and 2) binding endogenous MDM2 as a PROTAC E3 ligand for PROTAC-based degradation of other oncogenic proteins. In this review, we summarize current progress in the discovery and development of MDM2-based PROTAC drugs, and discuss future perspectives and challenges in their application as effective treatments for human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, researchers designed Proteolysis-targeting chimera (PROTAC) degraders based on MDM2 inhibitors.375”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [375]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Self-citationSchneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
Research works printed but not linked: 82
- RM Mohammad, 2009, An MDM2 Antagonist (MI-319) Restores p53 Functions and Increases the Life Span of Orally Treated Follicular Lymphoma Bearing Animals, Molecular Cancer, 8, 115, 10.1186/1476-4598-8-115 · DOI
- LT Vassilev, 2004, In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
- S Shangary, 2008, Targeting the MDM2-p53 Interaction for Cancer Therapy, Clinical Cancer Research, 14, 5318, 10.1158/1078-0432.CCR-07-5136 · DOI · Paper page
- S Kumari, 2022, Therapeutic Potential of p53 Reactivation in Prostate Cancer: Strategies and Opportunities, European Journal of Pharmacology, 919, 10.1016/j.ejphar.2022.174807 · DOI
- S Nag, 2014, Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?, Current Medicinal Chemistry, 21, 553, 10.2174/09298673113206660325 · DOI
- AB Herrero, 2016, Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma, International Journal of Molecular, 17, 2003
- Chao, 2015, Mechanisms of p53 Degradation, Clinica Chimica Acta, 438, 139, 10.1016/j.cca.2014.08.015 · DOI
- J Hu, 2021, Targeting Mutant p53 for Cancer Therapy: Direct and Indirect Strategies, Journal of Hematology and Oncology, 14, 157, 10.1186/s13045-021-01169-0 · DOI · Paper page
- R Rusiecki, 2019, MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010–Present), Recent Patents on Anti-Cancer Drug Discovery, 14, 324, 10.2174/1574892814666191022163540 · DOI
- A Burgess, 2016, Clinical Overview of MDM2/X-Targeted Therapies, Frontiers in Oncology, 6, 7, 10.3389/fonc.2016.00007 · DOI · Paper page
- S Zhang, 2021, Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions, Journal of Medicinal Chemistry, 64, 10621, 10.1021/acs.jmedchem.1c00940 · DOI
- J Myung, 2001, The Ubiquitin-Proteasome Pathway and Proteasome Inhibitors, Medicinal Research Reviews, 21, 245, 10.1002/med.1009 · DOI · Paper page
- Z Yang, 2021, Merging PROTAC and Molecular Glue for Degrading BTK and GSPT1 Proteins Concurrently, Cell Research, 31, 1315, 10.1038/s41422-021-00533-6 · DOI
- K Garber, 2022, The PROTAC Gold Rush, Nature Biotechnology, 40, 12, 10.1038/s41587-021-01173-2 · DOI
- S He, 2022, Strategies for Designing Proteolysis Targeting Chimaeras (PROTACs), Medicinal Research Reviews, 42, 1280, 10.1002/med.21877 · DOI
- M Bekes, 2022, PROTAC Targeted Protein Degraders: The Past is Prologue, Nature Reviews Drug Discovery, 21, 181, 10.1038/s41573-021-00371-6 · DOI · Paper page
- T Neklesa, 2019, ARV-110: An Oral Androgen Receptor PROTAC Degrader for Prostate Cancer, Journal of Clinical Oncology, 37, 259, 10.1200/JCO.2019.37.7_suppl.259 · DOI · Paper page
- W Xiang, 2021, Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer, Journal of Medicinal Chemistry, 64, 13487, 10.1021/acs.jmedchem.1c00900 · DOI
- X Yu, 2021, Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders, Journal of Medicinal Chemistry, 64, 18054, 10.1021/acs.jmedchem.1c01476 · DOI
- X Han, 2019, Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands, Journal of Medicinal Chemistry, 62, 11218, 10.1021/acs.jmedchem.9b01393 · DOI · Paper page
- LJ Zhao, 2020, A Highly Potent PROTAC Androgen Receptor (AR) Degrader ARD-61 Effectively Inhibits AR-Positive Breast Cancer Cell Growth in Vitro Tumor Growth in Vivo, Neoplasia, 22, 522, 10.1016/j.neo.2020.07.002 · DOI
- S Kregel, 2020, Androgen Receptor Degraders Overcome Common Resistance Mechanisms Developed During Prostate Cancer Treatment, Neoplasia, 22, 111, 10.1016/j.neo.2019.12.003 · DOI
- X Han, 2019, Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer, Journal of Medicinal Chemistry, 62, 941, 10.1021/acs.jmedchem.8b01631 · DOI · Paper page
- J Hu, 2019, Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER), Journal of Medicinal Chemistry, 62, 1420, 10.1021/acs.jmedchem.8b01572 · DOI · Paper page
- L Bai, 2019, A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo, Cancer Cell, 36, 498, 10.1016/j.ccell.2019.10.002 · DOI · Paper page
- Y Zou, 2019, The PROTAC Technology in Drug Development, Cell Biochemistry & Function, 37, 21, 10.1002/cbf.3369 · DOI · Paper page
- CY Yang, 2019, Small-Molecule PROTAC Degraders of the Bromodomain and Extra Terminal (BET) Proteins – A Review, Drug Discovery Today Technologies, 31, 43, 10.1016/j.ddtec.2019.04.001 · DOI
- JS Schneekloth, 2004, Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation, Journal of the American Chemical Society, 126, 3748, 10.1021/ja039025z · DOI · Paper page
- D Bernard, 2012, AM-8553: A Novel MDM2 Inhibitor with a Promising Outlook for Potential Clinical Development, Journal of Medicinal Chemistry, 55, 4934, 10.1021/jm3007068 · DOI
- Y Zhao, 2013, A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice, Journal of Medicinal Chemistry, 56, 5553, 10.1021/jm4005708 · DOI · Paper page
- A Zafar, 2021, Targeting the p53-MDM2 Pathway for Neuroblastoma Therapy: Rays of Hope, Cancer Letters, 496, 16, 10.1016/j.canlet.2020.09.023 · DOI
- W Wang, 2012, Small Molecule Agents Targeting the p53-MDM2 Pathway for Cancer Therapy, Medicinal Research Reviews, 32, 1159, 10.1002/med.20236 · DOI
- GM Popowicz, 2011, The Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious, Angewandte Chemie International Edition in English, 50, 2680, 10.1002/anie.201003863 · DOI · Paper page
- C Tovar, 2013, MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models, Cancer Research, 73, 2587, 10.1158/0008-5472.CAN-12-2807 · DOI · Paper page
- B Vu, 2013, Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development, ACS Medicinal Chemistry Letters, 4, 466, 10.1021/ml4000657 · DOI · Paper page
- M de Jonge, 2017, A Phase I Study of SAR405838, A Novel Human Double Minute 2 (HDM2) Antagonist, in Patients with Solid Tumours, European Journal of Cancer, 76, 144, 10.1016/j.ejca.2017.02.005 · DOI · Paper page
- J Jung, 2016, TP53 Mutations Emerge with HDM2 Inhibitor SAR405838 Treatment in De-Differentiated Liposarcoma, Nature Communication, 7, 10.1038/ncomms12609 · DOI · Paper page
- M Konopleva, 2020, MDM2 Inhibition: An Important Step Forward in Cancer Therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
- Y Liu, 2019, The Past, Present and Future of Potential Small-Molecule Drugs Targeting p53-MDM2/MDMX for Cancer Therapy, European Journal of Medicinal Chemistry, 176, 92, 10.1016/j.ejmech.2019.05.018 · DOI
- T Stachyra-Valat, 2016, NVP-HDM201: Biochemical and Biophysical Profile of a Novel Highly Potent and Selective PPI Inhibitor of p53-Mdm2, Cancer Research, 76, 1239, 10.1158/1538-7445.AM2016-1239 · DOI · Paper page
- MM Gounder, 2016, A Phase 1 Study of the MDM2 Inhibitor DS-3032b in Patients (pts) with Advanced Solid Tumors and Lymphomas, Journal of Clinical Oncology, 34, 2581, 10.1200/JCO.2016.34.15_suppl.2581 · DOI
- CD DiNardo, 2016, Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies – Preliminary Results, Blood, 128, 593, 10.1182/blood.V128.22.593.593 · DOI
- L Zhang, 2019, A Novel Small Molecule Inhibitor of MDM2-p53 (APG-115) has Antitumor Activity in Gastric Adenocarcinoma, Cancer Research, 79, 2061, 10.1158/1538-7445.AM2019-2061 · DOI
- H Yi, 2018, A Novel Small Molecule Inhibitor of MDM2-p53 (APG-115) Enhances Radiosensitivity of Gastric Adenocarcinoma, Journal of Experimental & Clinical Cancer Research, 37, 97, 10.1186/s13046-018-0765-8 · DOI · Paper page
- F Ravandi, 2016, A Phase I Trial of the Human Double Minute 2 Inhibitor (MK-8242) in Patients with Refractory/Recurrent Acute Myelogenous Leukemia (AML), Leukemia Research, 48, 92, 10.1016/j.leukres.2016.07.004 · DOI · Paper page
- T Valat, 2014, Mechanistic Study of NVP-CGM097: A Potent, Selective and Species Specific Inhibitor of p53-Mdm2, Cancer Research, 74, 1798, 10.1158/1538-7445.AM2014-1798 · DOI
- F Gessier, 2015, Discovery of Dihydroisoquinolinone Derivatives as Novel Inhibitors of the p53-MDM2 Interaction with a Distinct Binding Mode, Bioorganic and Medicinal Chemistry Letters, 25, 3621, 10.1016/j.bmcl.2015.06.058 · DOI
- Y Wang, 2014, Optimization Beyond AMG 232: Discovery and SAR of Sulfonamides on a Piperidinone Scaffold as Potent Inhibitors of the MDM2-p53 Protein-Protein Interaction, Bioorganic and Medicinal Chemistry Letters, 24, 3782, 10.1016/j.bmcl.2014.06.073 · DOI
- SM Picksley, 1993, The p53-mdm2 Autoregulatory Feedback Loop: A Paradigm for the Regulation of Growth Control by p53?, Bioessays, 15, 689, 10.1002/bies.950151008 · DOI · Paper page
- GM Burslem, 2017, Small-Molecule Modulation of Protein Homeostasis, Chemical Reviews, 117, 11269, 10.1021/acs.chemrev.7b00077 · DOI · Paper page
- M Toure, 2016, Small-Molecule PROTACS: New Approaches to Protein Degradation, Angewandte Chemie International Edition, 55, 1966, 10.1002/anie.201507978 · DOI · Paper page
- AC Lai, 2016, Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL, Angewandte Chemie International Edition, 55, 807, 10.1002/anie.201507634 · DOI · Paper page
- PM Cromm, 2017, Targeted Protein Degradation: From Chemical Biology to Drug Discovery, Cell Chemical Biology, 24, 1181, 10.1016/j.chembiol.2017.05.024 · DOI · Paper page
- AC Lai, 2017, Induced Protein Degradation: An Emerging Drug Discovery Paradigm, Nature Reviews Drug Discovery, 16, 101, 10.1038/nrd.2016.211 · DOI · Paper page
- H Inuzuka, 2022, PROTAC Technology for the Treatment of Alzheimer’s Disease: Advances and Perspectives, Acta Materia Medica, 1, 24, 10.15212/AMM-2021-0001 · DOI
- J Liu, 2021, Cancer Selective Target Degradation by Folate-Caged PROTACs, Journal of the American Chemical Society, 143, 7380, 10.1021/jacs.1c00451 · DOI · Paper page
- A Testa, 2018, 3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation, Journal of the American Chemical Society, 140, 9299, 10.1021/jacs.8b05807 · DOI
- M Slabicki, 2020, Small-Molecule-Induced Polymerization Triggers Degradation of BCL6, Nature, 588, 164, 10.1038/s41586-020-2925-1 · DOI · Paper page
- F Yu, 2021, Targeting Protein Kinases Degradation by PROTACs, Frontiers in Chemistry, 9
- H Li, 2022, Drug Discovery is an Eternal Challenge for the Biomedical Sciences, Acta Materia Medica, 1, 1
- MJ Bond, 2021, Proteolysis Targeting Chimeras (PROTACs) Come of Age: Entering the Third Decade of Targeted Protein Degradation, RSC Chemical Biology, 2, 725, 10.1039/D1CB00011J · DOI · Paper page
- JC Groppe, 2019, Induced Degradation of Protein Kinases by Bifunctional Small Molecules: a Next-Generation Strategy, Expert Opinion on Drug Discovery, 14, 1237, 10.1080/17460441.2019.1660641 · DOI
- X Sun, 2019, PROTACs: Great Opportunities for Academia and Industry, Signal Transduction and Targeted Therapy, 4, 64, 10.1038/s41392-019-0101-6 · DOI · Paper page
- B Wang, 2021, Development of MDM2 Degraders Based on Ligands Derived From Ugi Reactions: Lessons and Discoveries, European Journal of Medicinal Chemistry, 219, 10.1016/j.ejmech.2021.113425 · DOI · Paper page
- B Zhang, 2015, Small-Molecule MDM2-p53 Inhibitors: Recent Advances, Future Medicinal Chemistry, 7, 631, 10.4155/fmc.15.13 · DOI
- Q Zhao, 2019, Induction of Apoptosis in MDA-MB-231 Breast Cancer Cells by a PARP1-Targeting PROTAC Small Molecule, Chemical Communications (Camb), 55, 369, 10.1039/C8CC07813K · DOI · Paper page
- L Bai, 2017, Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer, Cancer Research, 77, 2476, 10.1158/0008-5472.CAN-16-2622 · DOI · Paper page
- N Ohoka, 2019, Development of Small Molecule Chimeras that Recruit Arylhydrocarbon Receptor (AhR) E3 Ligase to Induce Degradation of Target Proteins, Molecular Cancer Therapeutics, 18, C125, 10.1158/1535-7163.TARG-19-C125 · doi:10.1158/1535-7163.targ-19-c125
- M Zengerle, 2015, Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4, ACS Chemical Biology, 10, 1770, 10.1021/acschembio.5b00216 · DOI · Paper page
- KH Chan, 2018, Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds, Journal of Medicinal Chemistry, 61, 504, 10.1021/acs.jmedchem.6b01912 · DOI · Paper page
- F Li, 2022, Poly (ADP-ribose) Polymerase 1 (PARP1) Inhibition Promotes Pulmonary Metastasis of Osteosarcoma by Boosting Ezrin Phosphorylation, International Journal of Biological Sciences, 18, 1238, 10.7150/ijbs.58784 · DOI
- S Challa, 2022, Two Birds, One Stone: Non-canonical Therapeutic Effects of the PARP Inhibitor Talazoparib, Cell Chemical Biology, 29, 171, 10.1016/j.chembiol.2022.02.002 · doi:10.1016/j.chembiol.2022.02.002
- M Mekhaeil, 2022, Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases, Cancers (Basel), 14, 687, 10.3390/cancers14030687 · DOI
- Y Jia, 2021, Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells, Frontiers in Oncology, 11
- X Zhang, 2020, Design and Synthesis of Selective Degraders of EGFR(L858R/T790M) Mutant, European Journal of Medicinal Chemistry, 192, 10.1016/j.ejmech.2020.112199 · DOI
- B Zhao, 2019, TrkC-Targeted Kinase Inhibitors and PROTACs, Molecular Pharmaceutics, 16, 4313, 10.1021/acs.molpharmaceut.9b00673 · DOI
- M Zheng, 2021, Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP, Journal of Medicinal Chemistry, 64, 7839, 10.1021/acs.jmedchem.1c00649 · DOI · Paper page
- WH Guo, 2020, Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry, Nature Communications, 11, 4268, 10.1038/s41467-020-17997-6 · DOI · Paper page
- D Takahashi, 2019, AUTACs: Cargo-Specific Degraders Using Selective Autophagy, Molecular Cell, 76, 797, 10.1016/j.molcel.2019.09.009 · DOI · Paper page
- B Ma, 2022, Kill Two Birds with One Stone: A Multifunctional Dual-Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome-Positive Leukemia, Advanced Science (Weinh), 9
- G Nishiguchi, 2021, Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators, Journal of Medicinal Chemistry, 64, 7296, 10.1021/acs.jmedchem.0c01313 · DOI
- B Halford, 2021, Arvinas Unveils PROTAC Structures, Chemical and Engineering News, 99, 5, 10.47287/cen-09914-scicon1 · DOI
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Metadata
- Authors
- Han, X., Wei, W., & Sun, Y.
- Venue
- Acta Materia Medica
- Publisher
- Compuscript, Ltd.
- Published
- 2022
- Volume
- 1
- Issue
- 2
- ISSN
- 2737-7946
- Cited by
- 35
- References
- 37
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. https://app.cochat.ai/papers/10.15212/amm-2022-0010
- The paper
- Han, X., Wei, W., & Sun, Y. (2022). PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. Acta Materia Medica. https://doi.org/10.15212/amm-2022-0010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.